Ovarian cancer aetiology: Facts and fiction

Journal of Family Planning and Reproductive Health Care

Volumn 32, Issue 2, 2006, Pages 82-86

  Elmasry, Karim ^a   Gayther, Simon A ^a  

^a Windeyer Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CONTRACEPTIVE AGENT; ESTROGEN; TALC;

CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; DEMOGRAPHY; DIET; ENDOMETRIOSIS; EPITHELIUM CELL; ESTROGEN THERAPY; FAMILY HISTORY; GEOGRAPHY; HEREDITY; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; INFERTILITY; LACTATION; MENARCHE; MENOPAUSE; NONHUMAN; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PARITY; PELVIC INFLAMMATORY DISEASE; PELVIS SURGERY; REVIEW; STROMA;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFERTILITY; MENARCHE; MENOPAUSE; OVARIAN NEOPLASMS; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT;

EID: 33646010069     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118906776276297     Document Type: Review

References (72)

1. Office of National Statistics. Cancer Statistics: Registrations 2001. London, UK: HMSO, 2001. http://www.statistics.gov.uk/downloads/theme_health/ MB1_32/MB1_32.pdf [Accessed 16 December 2006].
2. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971; 2: 163.
3. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721.
4. Stadel BV. The etiology and prevention of ovarian cancer (Letter). Am J Obstet Gynecol 1975; 123: 772-774.
5. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol 1995; 5: 310-314.
6. Elmasry K, Gayther SA. Somatic genetic mutations and clinical outcome in gynaecological cancers. Gynaecol Forum 2005; 10: 5-11.
7. Surveillance Epidemiology and End Results (SEER) Program of the National Cancer Institute, National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA. http://seer.cancer.gov/ [Accessed 16 December 2005].
8. GLOBOCAN 2002 database project hosted by the Descriptive Epidemiology Group, International Agency for Research on Cancer, Lyon, France. http://www-dep.iarc.fr/ [Accessed 16 December 2005].
9. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
10. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60: 496-504.
11. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695.
12. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
13. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430-433.
14. Cramer DW, Hutchison GB, Welch WR, Scully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst 1983; 71: 711-716.
15. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002; 156: 363-373.
16. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1184-1203.
17. Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995; 62: 678-684.
18. Polychronopoulou A. Tzonou A, Hsieh CC, Kaprinis G, Rebelakos A. Toupadaki N, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993; 55: 402-407.
19. Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995; 76: 284-290.
20. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60: 592-598.
21. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344: 1250-1254.
22. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140: 585-597.
23. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997; 67: 1005-1012.
24. Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990; 43: 559-568.
25. Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1993; 22: 192-197.
26. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 1987; 316: 650-655.
27. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994; 139: 654-661.
28. 2K Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80: 708-714.
29. Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991; 43: 543-556.
30. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991; 49: 61-65.
31. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144: 363-372.
32. Rosenblatt KA, Thomas DB, Noonan EA. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 1992; 28A: 1872-1876.
33. Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 1983; 249: 2909-2912.
34. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 235-240.
35. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 424-428.
36. Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004; 91: 1911-1915.
37. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 1998; 70: 1049-1055.
38. Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG. Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 1997; 12: 2159-2161.
39. Dor J, Lerner-Geva L, Rabinovici J. Chetrit A, Levran D, Lunenfeld B, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77: 324-327.
40. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17: 2209-2213.
41. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999; 354: 1586-1590.
42. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 334-341.
43. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285: 1460-1465.
44. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94: 497-504.
45. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739-1748.
46. Graham J, Graham R. Ovarian cancer and asbestos. Environ Res 1967; 1: 115-128.
47. Venter PF, Iturralde M. Migration of a particulate radioactive tracer from the vagina to the peritoneal cavity and ovaries. S Afr Med J 1979; 55: 917-919.
48. Cramer DW, Liberman RF, Titus-Ernstoff L, Welch WR, Greenberg ER, Baron JA, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999; 81: 351-356.
49. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br J Cancer 1995; 71: 1340-1342.
50. Miracle-McMahill HL, Calle EE, Kosinski AS, Rodriguez C, Wingo PA, Thun MJ, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol 1997; 145: 349-357.
51. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997: 71: 948-951.
52. Kreiger N, Sloan M, Cotterchio M, Parsons P. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol 1997; 26: 710-715.
53. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993; 270: 2813-2818.
54. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000; 77: 298-304.
55. Takahashi K, Kurioka H, Irikoma M, Ozaki T, Kanasaki H, Miyazaki K. Benign or malignant ovarian neoplasms and ovarian endometriomas. J Am Assoc Gynecol Laparosc 2001; 8: 278-284.
56. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol 1993; 169: 181-182.
57. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996; 88(4 Pt 1): 554-559.
58. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522-525.
59. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 447-451.
60. Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 667-669.
61. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11: 111-117.
62. Hisada M, van den Berg BJ, Strickler HD, Christianson RE, Wright WE, Waters DJ, et al. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control 2001; 12: 335-341.
63. Risch HA, Jain M, Marrett LD, Howe GR. Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes Control 1994; 5: 540-548.
64. La Vecchia C, Decarli A, Negri E, Parazzini F, Gentile A, Cecchetti G, et al. Dietary factors and the risk of epithelial ovarian cancer. J Natl Cancer Inst 1987; 79: 663-669.
65. Kushi LH, Mink PJ, Folsom AR, Anderson KE, Zheng W, Lazovich D, et al. Prospective study of diet and ovarian cancer. Am J Epidemiol 1999; 149: 21-31.
66. Fairfield KM, Hankinson SE, Rosner BA, Hunter DJ, Colditz GA, Willett WC. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 2001; 92: 2318-2326.
67. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control 2001; 12: 855-863.
68. Kuper H, Cramer DW, Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? Cancer Causes Control 2002; 13: 455-463.
69. Lubin F, Chetrit A, Freedman LS, Alfandary E, Fishier Y, Nitzan H, et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol 2003; 157: 113-120.
70. Lukanova A, Toniolo P, Lundin E, Micheli A, Akhmedkhanov A, Muti P, et al. Body mass index in relation to ovarian cancer: a multicentre nested case-control study. Int J Cancer 2002; 99: 603-608.
71. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003; 95: 1244-1248.
72. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol 2002; 100: 288-296.